US Patent

US10849916 — Stable liquid formulations of cyclophosphamide and its impurities

Formulation · Assigned to Dr Reddys Laboratories Ltd · Expires 2035-07-13 · 9y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable liquid formulations of the cancer drug cyclophosphamide, including certain impurities, for parenteral administration.

USPTO Abstract

The present invention relates to novel impurities of cyclophosphamide having structure V, VI or VII, stabilized form of these novel impurities, a process of preparing a stabilized form and isolating thereof. The invention also relates cyclophosphamide formulations which include cyclophosphamide, at least one pharmaceutically acceptable excipient, and a certain level of these impurities having structure V, VI or VII. The invention further relate to method of using such stable liquid formulations of cyclophosphamide for parenteral administration in treating various cancer disorders.

Drugs covered by this patent

Patent Metadata

Patent number
US10849916
Jurisdiction
US
Classification
Formulation
Expires
2035-07-13
Drug substance claim
No
Drug product claim
Yes
Assignee
Dr Reddys Laboratories Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.